The Non Invasive Frontier: Liquid Biopsy Companies Refining Healthcare

Cancer has high mortality rate, primarily because of the delayed detection and complexities of current diagnostic procedures. The mortality rates associated with cancer can be significantly reduced if the efforts shift towards the development of methods for early detection of cancer. Amid the increasing burden of cancer and the limitations of traditional tissue biopsies, there is an evident surge in the demand for safe, non-invasive, and versatile diagnostic options. In this evolving landscape, liquid biopsy companies play a pivotal role. Liquid biopsy has emerged as an effective alternative. Once cancer is suspected, diagnosis is usually made by pathologists, onco-pathologists, and imaging radiologists.

According to the SEER statistics, nearly 13% women are anticipated to be diagnosed with breast cancer at some point during their lifetime. Various advanced non-invasive or minimally invasive methods, championed by liquid biopsy companies, are surpassing the constraints of invasive diagnostic procedures. These non-invasive approaches for cancer screening and diagnosis encompass standard physical diagnostic imaging tools, screening assays that use body fluids to confirm the presence of tumors, and other advanced techniques such as liquid biopsies, all of which are contributing to a transformative shift in the field of oncology.

Various benefits associated with non invasive cancer diagnostics are likely to contribute to the growing adoption of liquid biopsy products

Various benefits associated with non invasive cancer diagnostics are likely to contribute to the growing adoption of liquid biopsy products

Opportunities Associated with Liquid Biopsy Domain

Market opportunities are favorable circumstances or situations within a market that can be leveraged by businesses to achieve growth, profitability, and success. These opportunities can arise from emerging technologies, untapped customer segments, changing market dynamics, evolving consumer needs, regulatory developments, and other factors that present avenues for businesses to expand their operations and capture market share.

  • Growing Demand for Liquid Biopsy: The global population is continuously increasing, leading to a higher prevalence of cancer diagnosis. With traditional tissue biopsies being invasive and sometimes impractical for routine screening, there’s a growing demand for non-invasive alternatives. Liquid biopsy, which allows for the detection of cancer-related biomarkers in blood or other bodily fluids, has gained prominence as an effective and less invasive method for cancer diagnosis. This increasing demand presents a substantial market opportunity for companies that manufacture liquid biopsy products, including assay kits and related technologies.
  • Expanding Horizons and Acquisition Trends: Liquid biopsy has gained wide acceptance, particularly in developed countries where healthcare systems prioritize early cancer detection. Notably, there has been a surge in acquisitions of companies specializing in liquid biopsy products by established industry players. This trend reflects the keen interest of these established players in incorporating liquid biopsy capabilities into their portfolios. Liquid biopsy companies aim to diversify their offerings, meet the growing demand for non-invasive diagnostics, and stay competitive in the evolving landscape of cancer diagnosis.
  • Increasing Investment in Research and Development: The increasing investments in research and development between healthcare institutions, research organizations, and biotechnology companies are driving innovation in this domain. This innovation has the potential to accelerate the development of cutting-edge non-invasive cancer diagnostics and foster greater adoption of liquid biopsy products.

Current Market Landscape

Over 345 liquid biopsy companies including industry and non-industry players, are actively engaged in the manufacturing of non-invasive cancer diagnostics with enhanced efficacy. Notably, North America has emerged as the hub for this dynamic industry, featuring the presence of approximately 60% of these manufacturers. The market is currently characterized by a mix of well-established firms and emerging liquid biopsy companies, collectively driving innovation and progress in the non invasive cancer diagnostics market.

Liquid Biopsy Product Portfolio

The liquid biopsy product portfolio includes over 175 liquid biopsy products that are either launched or under development, reflecting the active involvement of various liquid biopsy companies. It is noteworthy that more than 80% of these liquid biopsy products are commercially available, with 90% of them offered as assay kits. Furthermore, nearly 60% of the liquid biopsy products in the portfolio are currently under development for the detection of circulating tumor DNA, indicating the innovation and ongoing commitment of liquid biopsy companies in advancing cancer diagnostics

The liquid biopsy product portfolio includes over 175 liquid biopsy products that are either launched or under development, reflecting the active involvement of various liquid biopsy companies.

Exploring a diverse array of liquid biopsy products, manufacturers and key parameters in cancer detection

Partnerships and Collaborations: Exhibiting High Activity of Liquid Biopsy Companies Engaged in this Domain

The growing interest in this field is evident from the surge in partnership activity. More than 40% of these deals were established in the last two years, with 2021 marking a year of particularly intensive collaboration among liquid biopsy companies. Product / technology development agreements have taken a substantial share in these partnerships related to liquid biopsy. This was closely followed by product / technology utilization agreements, reflecting the significant involvement of liquid biopsy companies in forging alliances and driving innovation in the field.

Stakeholders in the liquid biopsy industry have forged several partnerships in order to enhance their liquid biopsy product portfolio.

Various collaborations in liquid biopsy domain based on the type of partnership model adopted by the stakeholders

Billions of Dollars are Being Invested in Funding the Initiatives of Various Players Engaged in the Liquid Biopsy Market

Close to USD 7.3 billion has been invested by both private and public investors in the liquid biopsy domain since 2015. Liquid biopsy companies, involved in the development of liquid biopsy products, have impressively raised around USD 4,243 million through venture funding, constituting 57% of the total capital raised during this period. Notably, more than 235 investors have actively financed various projects and initiatives driven by liquid biopsy companies, emphasizing the significant financial backing and interest in this innovative field. The below figure presents the distribution of funding and investment based on the type of funding.

Comprehensive representation of varied funding initiatives in the rapidly advancing liquid biopsy domain

Comprehensive representation of varied funding initiatives in the rapidly advancing liquid biopsy domain

Concluding Remarks:

In a nutshell, the rising demand for non-invasive cancer screening techniques has spurred numerous industry players and liquid biopsy companies to embark on initiatives for the development and advancement of liquid biopsy products. Furthermore, recognizing the potential benefits of early cancer diagnosis, patient monitoring, and recurrence tracking, industry players and liquid biopsy companies are dedicated to creating innovative liquid biopsy products. With the ongoing pace of innovation, coupled with encouraging partnership and funding activity and the relentless efforts of these industry and liquid biopsy companies, the liquid biopsy market is poised to witness substantial growth in the foreseeable future.

For detailed insights about this domain, check out our report on Liquid Biopsy Market